Plato Investment Management Ltd Takes $1.48 Million Position in IDEXX Laboratories, Inc. $IDXX

Plato Investment Management Ltd acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,836 shares of the company’s stock, valued at approximately $1,484,000.

Several other hedge funds also recently added to or reduced their stakes in IDXX. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories in the second quarter valued at $25,000. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth $26,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the period. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Finally, WealthCollab LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $30,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on IDXX. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. UBS Group upped their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup increased their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Stock Down 0.9%

Shares of NASDAQ:IDXX opened at $546.09 on Tuesday. The firm has a market capitalization of $43.02 billion, a PE ratio of 38.40, a price-to-earnings-growth ratio of 2.94 and a beta of 1.54. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm’s 50-day moving average is $560.74 and its two-hundred day moving average is $579.65.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the business posted $3.50 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.